Krause und Pachernegg
Verlag für Medizin und Wirtschaft
Artikel   Bilder   Volltext

Mobile Version
A-  |   A  |   A+
Werbung
 
Dia-Präsentation von SERVIER
EUROPA-Studie (Perindopril) (60 Abbildungen)
Übersicht
Gesamtpräsentation zum Download (rechte Maustaste und "Ziel speichern unter..." klicken)


Zum ersten Bild Abb. 8: KHK - Sekundärprävention Abb. 9: EUROPA-Studie - Hypothese Abb. 10: EUROPA-Studie - Perindopril Aktuelles Bild - Abb. 11: EUROPA-Studie - Blutdruck Abb. 12: Perindopril - Gewebs-ACE Abb. 13: Perindopril - Bradykinin Abb. 14: Perindopril - Endotheliale Dysfunktion Zum letzten Bild
Abbildung 11: EUROPA-Studie - Blutdruck
The blood pressure reduction over 24 h minimizes the risk of stroke and myocardial infarction in the early morning hours. In the randomized, parallel study, 293 mild-to-moderate essential hypertensive patients were treated with perindopril 4 to 8 mg once daily or placebo for 12 weeks. Trough-to-peak ratio (TPR) in placebo-corrected diastolic blood pressure at 24 h versus 6 h was 100 %, and 97 % for 4 mg and 8 mg, respectively. A linear relationship in efficacy between the dose of perindopril and the reduction in blood pressure was demonstrated over the range of 4 mg to 8 mg once daily over the 24 h.
 
EUROPA-Studie - Blutdruck
Vorheriges Bild Nächstes Bild   


Abbildung 11: EUROPA-Studie - Blutdruck
The blood pressure reduction over 24 h minimizes the risk of stroke and myocardial infarction in the early morning hours. In the randomized, parallel study, 293 mild-to-moderate essential hypertensive patients were treated with perindopril 4 to 8 mg once daily or placebo for 12 weeks. Trough-to-peak ratio (TPR) in placebo-corrected diastolic blood pressure at 24 h versus 6 h was 100 %, and 97 % for 4 mg and 8 mg, respectively. A linear relationship in efficacy between the dose of perindopril and the reduction in blood pressure was demonstrated over the range of 4 mg to 8 mg once daily over the 24 h.
 
copyright © 2003–2017 Krause & Pachernegg GmbH | Sitemap | Impressum
 
Werbung